:::

TFDA construction of Pharmaceutical Plant of Controlled Drugs to be completed by July 2017

  • Data Source:Food and Drug Administration, Ministry of Health and Welfare
  • Created:2017-08-22
  • Last Updated:2017-08-23

 Taiwan Food and Drug Administration(TFDA)  has raised NT$490 million to implement the construction of a new plant and the renovation of the existing building of the Pharmaceutical Plant of Controlled Drugs division ( PPCD). This will help to improve the quality of controlled drugs and expand the production ability in Taiwan for Schedule 1 and Schedule 2 controlled drugs. This project, entrusted to Construction and Planning Agency, Ministry of the Interior, was launched on December 5, 2014 and was completed in July this year.

 PPCD was moved to Sanxia District, New Taipei City in 1955, and the existing plant, built in 1988, conforms to current international PIC/S GMP standard. Limited by the old facilities, the existing plant is unable to meet the increased demand of narcotic drugs for pain control and increase the production capacity sufficiently. Therefore, the new pharmaceutical plant which conforms to the PIC/S GMP standard was built.

 The new sevenstory plant has 2 basement floors, and a total floor area of approximately 7144 square meters (2161 pings). The design was built according to Green and Intelligent Building specifications and hopes to get certification for these. The main space includes clean zones for laboratories and manufacturing as well as materials storage rooms, . The plant has established two production lines as backup. After passing the PIC/S GMP assessment in the near future, the new plant will start production to increase the PPCD production capacity and pharmaceutical quality.

 PPCD is committed to steadily and sufficiently provide safe and high-quality Schedule I and Schedule II controlled drugs. In addition to continue improving the quality of pharmaceutical production, PPCD is dedicated to the research and development of new pharmaceutical forms and new products. The production capacity of the new plant is efficiently utilized to increase the production rate of Schedule 1 and Schedule 2 controlled drugs.